Skip to main content
. Author manuscript; available in PMC: 2020 Aug 5.
Published in final edited form as: Dev Cell. 2019 Jun 6;50(3):367–380.e7. doi: 10.1016/j.devcel.2019.05.017

Figure 6:

Figure 6:

Defective NEUROG3-E47 dimerization capability of NEUROG3 mutations. (A) Schematic model of relative NEUROG3-E47 heterodimerization capability test by competition loss of E47 homodimer binding onto Dll-1 E-box.

(B) E47 heterodimerization analysis with purified NEUROG3 variants.

(C) Quantification of E47 heterodimerization with purified NEUROG3 variants by loss of the signal of E47 homodimer binding onto Dll-1 E-box.

(D) Quantification of E47 heterodimerization with purified NEUROG3 variants by loss of the signal of E47 homodimer binding onto Dll-1 E-box.

For all experiments, the data is representative of a minimum of 3 separate experiments. Data are represented as mean ± SD. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001 for two-tailed student’s t-test or one-way ANOVA with Dunnett or Dunnett T3 (unequal variance) post hoc test. See also Figure S7.